How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

CrowdStrike's 2025 data shows attackers breach AI systems in 51 seconds. Field CISOs reveal how inference security platforms ...

Bun 1.3 revolutionizes full-stack JavaScript development with unified database APIs and zero-config frontend setup.

The world tried to kill Andy off but he had to stay alive to to talk about what happened with databases in 2025.

At the upcoming Visual Studio Live! Las Vegas developer conference, SQL expert Denny Cherry will share essential indexing ...

"We are justified by our works, not by our words." St. Clement Of Rome, "First Epistle to the Corinthians," c. 96 A.D. “But rather let us hasten with all energy and readiness of mind to perform every ...